Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Recommendations for medical management of hereditary breast and ovarian cancer: the Inserm-FNCLCC ad hoc committee
Autore:
Eisinger, F; Alby, N; Bremond, A; Dauplat, J; Espie, M; Janiaud, P; Kuttenn, F; Lebrun, JP; Lefranc, JP; Pierret, J; Sobol, H; Stoppa-Lyonnet, D; Thouvenin, D; Tristant, H; Feingold, J;
Indirizzi:
Inst J Paoli I Calmettes, INSERM CRI 9703, F-13009 Marseille, France Inst J Paoli I Calmettes Marseille France F-13009 3009 Marseille, France Ligue Natl Canc, Paris, France Ligue Natl Canc Paris FranceLigue Natl Canc, Paris, France Ctr Leon Berard, F-69373 Lyon, France Ctr Leon Berard Lyon France F-69373 tr Leon Berard, F-69373 Lyon, France CRLCC Jean Perrin, Clermont Ferrand, France CRLCC Jean Perrin Clermont Ferrand France rin, Clermont Ferrand, France Hop St Louis, Paris, France Hop St Louis Paris FranceHop St Louis, Paris, France INSERM, F-75654 Paris, France INSERM Paris France F-75654INSERM, F-75654 Paris, France Hop Necker Enfants Malad, Paris, France Hop Necker Enfants Malad Paris France cker Enfants Malad, Paris, France Hop La Pitie Salpetriere, Paris, France Hop La Pitie Salpetriere Paris France Pitie Salpetriere, Paris, France INSERM U304, CNRS, Paris, France INSERM U304 Paris FranceINSERM U304, CNRS, Paris, France INSERM CRI9703, Marseille, France INSERM CRI9703 Marseille FranceINSERM CRI9703, Marseille, France Inst Curie, Paris, France Inst Curie Paris FranceInst Curie, Paris, France Univ Paris 07, Ctr Etud Vivant, Paris, France Univ Paris 07 Paris France niv Paris 07, Ctr Etud Vivant, Paris, France INSERM U155, Paris, France INSERM U155 Paris FranceINSERM U155, Paris, France
Titolo Testata:
BULLETIN DU CANCER
fascicolo: 3, volume: 86, anno: 1999,
pagine: 307 - 313
SICI:
0007-4551(199903)86:3<307:RFMMOH>2.0.ZU;2-U
Fonte:
ISI
Lingua:
FRE
Soggetto:
FOLLOW-UP; MAMMOGRAPHY; FAMILIES; WOMEN;
Keywords:
BRCA1; BRCA2; breast cancer; guidelines; ovarian cancer; preventive care;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
25
Recensione:
Indirizzi per estratti:
Indirizzo: Eisinger, F InstMarseille, Calmettes, INSERM CRI 9703, 232 Blvd St Marguerite, F-13009 Inst J Paoli I Calmettes 232 Blvd St Marguerite Marseille France F-13009
Citazione:
F. Eisinger et al., "Recommendations for medical management of hereditary breast and ovarian cancer: the Inserm-FNCLCC ad hoc committee", B CANCER, 86(3), 1999, pp. 307-313

Abstract

Background: Almost 10% of breast and ovarian cancer are inherited, and themajority are linked to BRCA1 and BRCA2 germline mutations. Despite the uncertainty, consensus guidelines were defined to assist practitioners: and patients' decisions about the health care decisions to be made. Methodology: The ad hoc committee consisted of 14 experts designated by the French National Institute for Health and Medical Research. They all attended eleven workshops at which a systematic analytical review of move than 3,500 articles was carried out Five additional experts critically analyzed the first version of the report Process: Two thresholds were defined on a probability scale giving the risk of developing breast or ovarian cancer, to serve as a means of deciding as whether an intervention is worthwhile. The first threshold is that above which an intervention can be envisaged or recommended the second is that under which an intervention can be ruled out; between the two, the decision has to be made on a each by case basis. Screening and preventive strategies analyzed: About breast cancer: 1) hormonal interventions; 2) primary prevention (diet, family planning and chemoprevention); 3) screening (breast self-examination, clinician breast examination, tumor markers, imaging); 4) prophylactic mastectomy. About ovarian cancer: I) hormonal stimulation; 2) screening (clinical screening, ultrasound and tumor markers); 3) prophylactic oophorertomy. Main conclusions: With each strategy the following points were dealt with: the information to be delivered to the consultand, the procedure and the indications. The committee's opinion about BRCAmutation screening is that population-based or even large scale implementation are not justified The committee feels that specific management is indispensable and advocates the use of defined and evaluated procedures, and involvement in clinical trials.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/03/20 alle ore 09:22:17